The DexCom Inc. (DXCM) Insider John Lister Sold 3,560 Shares

The DexCom Inc. (DXCM) Insider John Lister Sold 3,560 Shares

DexCom Inc. (NASDAQ:DXCM) insider John Lister sold 3,560 shares of the company’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $84.41, for a total value of $300,499.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

John Lister also recently made the following trade(s): On Friday, September 9th, John Lister sold 3,560 shares of DexCom stock. The stock was sold at an average price of $93.65, for a total value of $333,394.00.

DexCom Inc. (NASDAQ:DXCM) opened at 82.02 on Thursday. The firm’s 50-day moving average price is $90.14 and its 200-day moving average price is $78.37. The company’s market cap is $6.88 billion. DexCom Inc. has a 1-year low of $47.92 and a 1-year high of $96.38.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.12. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. The firm earned $137.30 million during the quarter, compared to analysts’ expectations of $132.48 million. During the same quarter in the previous year, the company posted ($0.05) EPS. DexCom’s revenue for the quarter was up 47.3% on a year-over-year basis. Equities research analysts forecast that DexCom Inc. will post ($0.57) EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA increased its position in DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock valued at $105,000 after buying an additional 1,162 shares during the last quarter. Bellwether Investment Group LLC acquired a new stake in shares of DexCom during the second quarter worth about $119,000. Bank of Montreal Can acquired a new stake in shares of DexCom during the second quarter worth about $134,000. Capstone Asset Management Co. acquired a new stake in shares of DexCom during the third quarter worth about $205,000. Finally, CIBC Asset Management Inc acquired a new stake in shares of DexCom during the second quarter worth about $211,000. Institutional investors and hedge funds own 99.37% of the company’s stock.

DXCM has been the subject of several recent research reports. Zacks Investment Research cut DexCom from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 4th. BMO Capital Markets initiated coverage on DexCom in a research report on Friday, September 16th. They set an “outperform” rating and a $112.00 price target for the company. Desjardins raised DexCom from a “hold” rating to a “buy” rating in a research report on Friday, September 16th. Leerink Swann reissued an “outperform” rating and set a $90.00 price target on shares of DexCom in a research report on Wednesday, July 20th. Finally, BTIG Research cut DexCom from a “buy” rating to a “neutral” rating and set a $92.00 price target for the company. in a research report on Wednesday, September 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $95.08.

DexCom Company Profile

Related posts

Leave a Comment